This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Vericiguat oral


Oral formulations of vericiguat.

Drugs List

  • vericiguat 10mg film coated tablets
  • vericiguat 2.5mg film coated tablets
  • vericiguat 5mg film coated tablets
  • VERQUVO 10mg film coated tablets
  • VERQUVO 2.5mg film coated tablets
  • VERQUVO 5mg film coated tablets
  • Therapeutic Indications


    Symptomatic chronic cardiac failure with reduced ejection fraction

    Treatment of symptomatic chronic heart failure in patients with reduced ejection fraction and are stabilised after IV therapy from a recent decompensation event.


    Prior to commencing vericiguat therapy, care should be taken in order to optimise diuretic therapy and volume status to ensure patients are stabilised after the decompensation event, especially in patients with high NT-proBNP levels.


    The starting dose is 2.5mg once daily. Every 2 weeks, the dose should be doubled to meet the target maintenance dose of 10mg once daily.

    Patients with Renal Impairment

    Vericiguat is not recommended in patients with eGFR <15 mL/minute/1.73m2 at treatment initiation or on dialysis.

    Additional Dosage Information

    In the event of tolerability issues by the patient, such as systolic blood pressure reading less than 90mmHg, temporary down-titration or discontinuation of vericiguat is advised.

    Vericiguat may be crushed and mixed with water directly before administration for patients who are unable to swallow.


    Children under 18 years
    Systolic blood pressure below 100mmHg
    Renal dialysis
    Severe hepatic impairment

    Precautions and Warnings

    Autonomic dysfunction
    Glucose-galactose malabsorption syndrome
    Lactose intolerance
    Left ventricular outflow obstruction
    Renal impairment - eGFR below 15ml/minute/1.73m sq

    Advise patient dizziness may affect ability to drive or operate machinery
    Contains lactose
    Reduce dose or discontinue if excessive hypotension occurs
    Female: Ensure adequate contraception during treatment
    Advise patient not to take two doses on the same day if a dose is missed

    Pregnancy and Lactation


    Vericiguat is contraindicated during pregnancy.

    Use of vericiguat is contraindicated by the manufacturer. At the time of writing, there is no data from the use of vericiguat in humans but animal studies have shown reproductive toxicity and therefore potential risk cannot be ruled out.


    Vericiguat is contraindicated during breastfeeding.

    Use of vericiguat during breastfeeding is contraindicated by the manufacturer. At the time of writing, there is no published information regarding the presence of vericiguat in human milk. However, vericiguat is present in the milk of lactating rats. Effects on exposed infants are unknown.

    Side Effects

    Gastroesophageal reflux disease

    Further Information

    Last full review date: September 2021

    Reference Sources

    Summary of Product Characteristics: Verquvo 2.5mg tablets. Bayer plc. Revised July 2021.

    Summary of Product Characteristics: Verquvo 5mg tablets. Bayer plc. Revised July 2021.

    Summary of Product Characteristics: Verquvo 10mg tablets. Bayer plc. Revised July 2021.
    NICE Evidence Services Available at: Last accessed: 14 June 2022

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.